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Abstract
Background: Some psychotropic drugs are connected with prolongation of QT interval, increased risk
of cardiac arrhythmias and greater incidence of sudden death, especially when used in combination.
Concomitant use of antipsychotics and antidepressants is not rare in our clinical practice. The study
compares the length of QT interval in patients on monotherapy with an antipsychotic or an antidepressant
and patients taking polytherapy (an antipsychotic agent combined with an antidepressant).
Methods: Sixty-one hospitalized women who met the ICD-10 criteria for schizophrenia, schizoaffective
psychosis, delusional disorder and mood disorder were included in the study. The monotherapy group
was consisted of thirty-two women treated with an antipsychotic or an antidepressant while the
polytherapy group was composed of twenty-nine women treated with an antipsychotic agent plus an
antidepressant. Two electrocardiograms (ECGs) were obtained for each patient: the first was carried out
before the treatment and the second after two weeks of treatment.
Statistical analysis was carried out by SPSS program and included unpaired and paired t test and Fisher's
exact test.
Results: Mean baseline QTc values did not differ between the groups (439 ± 22 ms was the same value
found in the both groups; unpaired t test, p > 0.5). Mean QTc intervals after two weeks of treatment were
also similar (439 ± 24 ms in the monotherapy group and 440 ± 20 ms in the polytherapy group; unpaired
t test, p > 0.5). Fisher's exact test did not reveal significant difference in the number of patients with
borderline (451–470 ms) or prolonged (> 470 ms) QTc between groups, neither before treatment nor
after two weeks of treatment. Twenty two women of the total of sixty one patients (36%) had QTc > 450
ms before applying therapy.
Conclusion: We did not find significant QT prolongation in our patients after two weeks of treatment
with antipsychotics and/or antidepressants. The QTc interval length did not differ significantly in the
monotherapy and the polytherapy group. More than one third of included women exceeded the threshold
value of borderline QTc interval (450 ms) before starting treatment. This finding calls for caution when
prescribing drugs to female psychiatric patients, especially if they have other health problems.
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Psychotropic drugs are among medications connected
with prolongation of the QT interval and greater occur-
rence of sudden cardiac death [1-7]. The QT interval is the
sequence of the ECG from the beginning of the QRS com-
plex to the end of the T wave and represents the temporal
equivalent of ventricular depolarization and repolariza-
tion. Its value corrected for heart rate is referred as cor-
rected QT interval (QTc). There is no consensus about the
upper physiological limit for QTc [8]. European Medi-
cines Agency quotes different possible upper values (450
ms, 480 ms, and 500 ms) and calls for caution when
change from baseline exceeds 30–60 ms [9]. Significant
QT prolongation ("long QT syndrome", LQTS), inherited
or acquired, is associated with the increased susceptibility
to ventricular tachyarrhythmia "torsade de pointes" (TdP)
that either resolve spontaneously or deteriorate into ven-
tricular fibrillation and sudden death. In comparison to
men, women are at higher risk for developing TdP because
the feminine gender is associated with a longer baseline
QT interval, perhaps due to differences in circulating sex
hormones [10-13]. For females, QTc interval values more
than 450 ms are commonly used as borderline and those
over 470 ms as prolonged [14-16].
Congenital forms of LQT syndrome are due to autosomal
recessive (Jervell and Lange-Nielsen syndrome) or auto-
somal dominant (Romano-Ward syndrome) mutations of
several genes encoding for cardiac ion channels with con-
sequent disturbances in electrical activity of the heart [17-
22]. LQTS mutation carriers are present in one of 1000 to
3000 individuals [23].
Acquired long QT syndrome occurs when one or more
risk factors, such as drugs that block certain cardiac ion
channels, provoke a prolonged QT interval. Common
causes of acquired LQTS are several classes of drugs, e.g.
Class I and III antiarrhythmics, macrolides antibiotics,
antihistamines, antipsychotics and antidepressants [24].
International Registry for Drug-Induced Arrhythmias by
the University of Arizona [25] put some antipsychotics
among the drugs with the most prominent arrhyth-
mogenic activity (haloperidol, chlorpromazine, pimozide
and thioridazine); less capable to induce arrhythmias are
clozapine, lithium, quetiapine, risperidone, venlafaxine
and ziprasidone. Antidepressants (amitriptyline, clomi-
pramine, citalopram, fluoxetine, paroxetine and sertra-
line) are at lower risk if they are not combined with other
risk factors known to prolong the QT interval (e.g. con-
comitant therapy with QTc prolonging drugs or inhibitors
of cytochrome 450 enzymes, bradycardia, presence of
congenital LQTS, and electrolyte imbalance like hypoka-
laemia and hypocalcaemia). Some studies pointed out the
greater possibility for cardiac arrhythmias when antipsy-
chotic drugs are combined with antidepressants [26].
Because concomitant use of antipsychotics and antide-
pressants are not infrequent in our clinical practice we
decided to explore are there any differences in the length
of QTc between patients on monotherapy with an antip-
sychotic or an antidepressant and patients treated with
combination of these drugs (an antipsychotic plus an
antidepressant).
Methods
A prospective investigation was performed in Psychiatric
hospital Vrapče, Zagreb. Sixty one patients, all women,
were included in the study, as consecutively received
patients from January to September 2006. Informed con-
sents were obtained and the local ethic committee
approved the investigation. The patients met the ICD-10
(International Classification of Disease, 10th revision) cri-
teria for schizophrenia, schizoaffective psychosis, delu-
sional disorder and mood disorder. According to patient's
history, clinical examination and laboratory tests, patients
with liver or renal disorders, cardiovascular disease or psy-
choactive drugs dependence were not included in the
study. The use of depot-therapy in the month prior to
investigation and the use of fluoxetine (because of its long
half-life) were the exclusion criteria also.
The patients were free of drugs minimum 48 hours before
the first ECG and the blood samples were taken. Only the
use of lorazepam (up to 7.5 mg/d) was permitted. The sec-
ond ECG was carried out after two weeks of treatment. The
group 1 was on monotherapy (treated with an antipsy-
chotic or an antidepressant). The group 2 was on poly-
therapy (treated with an antipsychotic and an
antidepressant). As concomitant therapy in both groups
the use of biperiden or lorazepam was possible if neces-
sary. All daily antipsychotic and antidepressant doses
were converted to defined daily dose equivalents (DDD),
as defined by the World Health Organization, and the cur-
rent daily dose was categorized into less than one DDD
equivalent and one or more DDD equivalents [27].
All patients had normal liver and renal functions accord-
ing to normal values of transaminases, blood urea nitro-
gen and creatinine. The serum levels of potassium,
sodium and calcium ions were determined. Body weight
and height were measured and body mass index (BMI)
was calculated. ECG was performed by routine clinically
used 12-lead electrocardiogram apparatus which auto-
matically calculates the QTc interval. We are aware that
the method used is a limitation of this study because the
measurement by the cardiologist could have been more
accurate [28]. The length of QT interval was compared
before and after treatment in the same group and between
the groups; differences were statistically analysed. The sta-
tistical analysis was done using SPSS program 12.0 andPage 2 of 6
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exact test.
Results and discussion
Characteristics of patients and applied therapy
Sixty one patients were included in the study. Thirty two
women were receiving an antipsychotic or an antidepres-
sant (group 1) and twenty nine women were treated with
an antipsychotic in combination with an antidepressant.
The two groups did not differ significantly with respect to
age, duration of illness, BMI, smoking status and doses of
psychopharmacs converted to DDD equivalents (Table
1). In twenty patients (33%) doses of applied psycho-
tropic drugs were above DDD while forty one patients
(67%) had equal or smaller doses in comparison to DDD.
Table 2 show the frequency of applied antipsychotics and
antidepressants respectively in the both groups.
QTc interval
Mean baseline values of QTc in group 1 (439 ± 22 ms) and
group 2 (439 ± 22 ms) were similar (independent t test p
= 0,953) (Table 3). There were no significant differences
in the length of QTc between the groups after two weeks
of treatment also: the mean values were 439 ± 24 ms in
the group 1 and 440 ± 20 ms in the group 2 (independent
t test p = 0,878 (Table 3). In group 1 the length of QTc
before and after treatment was similar (dependent t test p
= 0.989); the same was observed in group 2 (dependent t
test p = 0.812). The two groups did not differ significantly
in the number of patients with QTc > 470 ms, not before
therapy (Fisher's exact test p = 0.600) neither after two
weeks of treatment (Fisher's exact test p = 0.674). There
were three women (9.4%) in the group 1 with the QTc
prolongation more than 30 ms from the baseline value
(prolongations were 30, 32, and 87 ms) and the same
number was found in the group 2 (10.3%), (prolonga-
tions were 44, 66, and 66 ms). Mean values of QTc pro-
longation in the group 1 and group 2 were 8 ± 17 ms and
9 ± 19 ms respectively (independent t test p = 0.840).
Our study did not reveal significant differences in the
mean QTc length between women treated with antipsy-
chotics or antidepressants and women who were treated
with both of these drugs. There was no significant QT pro-
longation after two weeks of treatment in the both groups
too. No one patient had QTc = 500 ms. Eight patients of
sixty one patients included in the study (13%) had QTc
intervals > 470 ms and/or the QTc prolongation of 30 ms
or more from the baseline value. Five of these eight
patients were from the monotherapy group: three women
who were taking fluphenazine (7.5 mg/d), venlafaxine
(37.5 mg/d) or mirtazapine (30 mg/d) had hypocalcae-
mia, one woman was on ziprasidone (160 mg/d) and the
last one (on fluphenazine 7.5 mg/d) had borderline QTc
before starting treatment. The rest three patients were in
the polytherapy group: one woman was treated with pro-
mazine (200 mg/d) and maprotiline (100 mg/d) and had
positive family history of sudden father's death; one
patient was on high antidepressant therapy: paroxetine
(40 mg/d) in combination with mirtazapine (30 mg/d)
and olanzapine (5 mg/d); the third one was treated with
promazine (75 mg/d) and venlafaxine (75 mg/d). All of
these eight patients had normal potassium and sodium
serum levels.
One potential explanation why we did not observe signif-
icant QT prolongation in women on combined psycho-
tropic therapy could be the dose of psychopharmacs
applied. In two third of included patients doses of antip-
sychotics and antidepressants were equal or below DDD,
in the group 1 and 2. The quantity of drug given to patient
was determined by psychiatrist who cured the patient and
was clinically determined. Further more, some authors
point out that DDD equivalents are smaller than chlo-
rpromazine or haloperidol equivalents used in some pre-
Table 1: Characteristics of patients
Group 1 (N = 32) Group 2 (N = 29)
Characteristic Patients in monotherapy Patients in polytherapy *p
Age, range (yr) 27–69 27–70
Age, mean ± SD (yr) 48.3 ± 8.8 48.6 ± 11.3 0.771
Duration of illness, mean ± SD (yr) 10.8 ± 7.3 10.7 ± 9.1 0.950
BMI, mean ± SD 25.1 ± 5.5 27.9 ± 5.5 0.059
**p
Smoking present, N (%) 16 (50.0) 15 (51.7) 1.000
Applied dose > DDD:
Dose of AP > DDD, N (%) 7 (21.9) 8 (27.6) 0.767
Dose of AD > DDD, N (%) 9 (28.1) 11 (37.9) 0.586
*p – 2-tailed t test; **p – 2-tailed Fisher Exact test; BMI – "body mass index";
DDD – "defined daily dose"; AP – antipsychotic; AD – antidepressantPage 3 of 6
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relatively small number of encompassed patients.
Hennessy and al. [4] found that treated schizophrenic
patients have longer QTc intervals and higher rates of car-
diac arrhythmias than control subjects but they could not
determine whether that finding was connected with schiz-
ophrenia or its treatment. We found in our study that a
great proportion of included patients (more than one
third) exceeded the threshold of borderline QTc values (>
450 ms) prior to treatment, and the mean duration of psy-
chiatric illness was more than 10 years. Possible explana-
tion for this finding could be that patients with
schizophrenia are at higher risk for other illnesses (e.g.
atherosclerosis and cardiac abnormalities) than people in
the general population [30,31].
Conclusion
We did not find significant differences in QTc length after
two weeks of treatment between patients treated with
antipsychotics or antidepressants and those treated with
combinations of these drugs. No one patient had QTc
interval equal or longer than 500 ms, not before therapy
neither after two weeks of therapy, but more than one
third of included women had borderline QTc values
before starting therapy. Our results encourage us in our
clinical work but not in manner to be less cautious when
prescribing psychopharmacs, especially in patients with
renal, hepatic, cardiovascular or other health problems.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JЖS conceived of the study, performed the statistical anal-
ysis and helped to draft the manuscript. VB, PB, MH and
MSŠ participated in the design of the study and collecting
patients for inclusion and helped to draft the manuscript.
VJ participated in the design of the study and interpreta-
Table 2: Characteristics of applied therapy
Group 1 (N = 32) Group 2 (N = 29)
Psychotropic drug Patients in monotherapy Patients in polytherapy
N of patients dose range (mg/d) N of patients dose range(mg/d)
AD used
Antipsychotic
Ziprasidone 3 120–160 1 120 map
Olanzapine 4 10–20 7 5–15 Mir,ven,par,fluo
Clozapine 1 100 - - -
Risperidone 3 3–5 1 4 map
Sulpiride 1 400 3 50–200 ser,clo
fluophenazine 7 5–8 6 2–15 tia,ser,par,map
Haloperidol 3 6–15 4 4–15 mir,map,esc,clo
Promazine - - 4 75–350 tia,ven,map
Quetiapine - - 2 300–500 par,fluo
zuclopenthixol - - 1 10 Fluo
AP used
Antidepressant
Mirtazapine 2 30 3 15–30 ol,hal
Fluvoxamine 1 150 - - -
Tianeptin 2 37.5 2 37.5 flu,pro,
Sertraline 2 50–100 2 50 sul,flu
Venlafaxine 2 37.5–75 4 37.5–150 ol,pro
Paroxetine - - 4 10–40 Ol,flu,que
Maprotiline 1 100 7 50–100 zip,ris,flu,hal
Fluoxetine - - 3 20–40 ol,que,zuc
escitalopram - - 1 15 Hal
clomipramine - - 3 25 sul,hal
AD – antidepressant: map-maprotiline, mir-mirtazapine, ven-venlafaxine, par-paroxetine, fluo-fluoxetine, ser-sertraline, clo-clomipramine, tia-
tianeptin, esc-escitalopram
AP -antipsychotic: ol-olanzapine, hal-haloperidol, flu-fluophenazine, pro-promazine, sul-sulpiride, que-quetiapine, zip-ziprasidone, ris-risperidone, 
zuc-zuclopenthixolPage 4 of 6
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